Design and synthesis of 1,1-disubstituted-1-silacycloalkane-based compound libraries.

The introduction of silicon in biologically-relevant molecules represents an interesting medicinal chemistry tactic. Its use is mainly confined to the fine-tuning of specific molecular properties and organosilicon compounds are underrepresented in typical screening libraries. As part of the European Lead Factory efforts to generate novel, drug discovery-relevant chemical matter, the design and synthesis of 1,1-disubstituted-1-silacycloalkane-based compound libraries is described.

[1]  B. Wünsch,et al.  Sila‐Haloperidol, a Silicon Analogue of the Dopamine (D2) Receptor Antagonist Haloperidol: Synthesis, Pharmacological Properties, and Metabolic Fate , 2008, ChemMedChem.

[2]  W. Bains,et al.  Silicon chemistry as a novel source of chemical diversity in drug design. , 2003, Current opinion in drug discovery & development.

[3]  J. Montana,et al.  Sila-venlafaxine, a Sila-Analogue of the Serotonin/Noradrenaline Reuptake Inhibitor Venlafaxine: Synthesis, Crystal Structure Analysis, and Pharmacological Characterization , 2006 .

[4]  R. Lamb,et al.  Exploring organosilane amines as potent inhibitors and structural probes of influenza a virus M2 proton channel. , 2011, Journal of the American Chemical Society.

[5]  A. Franz.  The synthesis of biologically active organosilicon small molecules. , 2007, Current opinion in drug discovery & development.

[6]  A. Franz,et al.  Organosilicon molecules with medicinal applications. , 2013, Journal of medicinal chemistry.

[7]  Asher Mullard,et al.  European Lead Factory opens for business , 2013, Nature Reviews Drug Discovery.

[8]  N. Meanwell.  Synopsis of some recent tactical application of bioisosteres in drug design. , 2011, Journal of medicinal chemistry.

[9]  G. Showell,et al.  Exploitation of silicon medicinal chemistry in drug discovery , 2004, Expert opinion on investigational drugs.

[10]  M. Brook.  Silicon in Organic, Organometallic, and Polymer Chemistry , 1999 .

[11]  R. Tacke,et al.  Sila-Analogues of High-Affinity, Selective σ Ligands of the Spiro[indane-1,4‘-piperidine] Type: Syntheses, Structures, and Pharmacological Properties , 2003 .

[12]  S. Sieburth,et al.  Silanediols: A New Class of Potent Protease Inhibitors. , 1998, Angewandte Chemie.

[13]  J. Montana,et al.  Trimethylsilylpyrazoles as novel inhibitors of p38 MAP kinase: a new use of silicon bioisosteres in medicinal chemistry. , 2007, Bioorganic & medicinal chemistry letters.

[14]  H. Lönnberg,et al.  Synthesis and pharmacological properties of 4(5)-(2-ethyl-2,3-dihydro-2 silainden-2-yl)imidazole, a silicon analogue of atipamezole , 1996 .

[15]  E. Lukevics,,et al.  Silyl modification of biologically active compounds , 1997 .

[16]  R. Tacke,et al.  The Si-2,4,6-Trimethoxyphenyl Moiety as a Novel Protecting Group in Organosilicon Chemistry: Alternative Synthesis of rac-Sila-venlafaxine , 2004 .